Oppenheimer analyst Jason Helfstein downgrades Redfin (NASDAQ:RDFN) from Perform to Underperform and announces $1.3 price target.
There’s Optimism Around Longboard Pharmaceuticals’ Anti-Seizure Candidate: Analyst Boosts Price Target
Tuesday, Longboard Pharmaceuticals Inc (NASDAQ: LBPH) released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of Developmental